<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Antidepressants | Domain 9 | MasteryPage</title>
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Instrument+Serif:ital@0;1&family=Inter:wght@300;400;500;600;700&display=swap" rel="stylesheet">
  <style>
    :root {
      --bg-primary: #09090b; --bg-secondary: #0f0f11; --bg-tertiary: #18181b; --bg-card: #1c1c1f;
      --text-primary: #fafafa; --text-secondary: #a1a1aa; --text-muted: #71717a;
      --accent: #ef4444; --accent-dim: rgba(239, 68, 68, 0.15);
      --border: rgba(255, 255, 255, 0.06); --gradient-gold: linear-gradient(135deg, #f59e0b 0%, #d97706 100%);
      --radius-sm: 8px; --radius-md: 12px; --radius-lg: 16px;
      --font-display: 'Instrument Serif', Georgia, serif; --font-body: 'Inter', -apple-system, sans-serif;
    }
    * { margin: 0; padding: 0; box-sizing: border-box; }
    body { font-family: var(--font-body); background: var(--bg-primary); color: var(--text-primary); line-height: 1.7; }
    .top-nav { position: fixed; top: 0; left: 0; right: 0; height: 72px; background: rgba(9, 9, 11, 0.95); backdrop-filter: blur(20px); border-bottom: 1px solid var(--border); z-index: 1000; display: flex; align-items: center; padding: 0 32px; }
    .nav-left { display: flex; align-items: center; gap: 24px; }
    .logo { display: flex; align-items: center; gap: 10px; text-decoration: none; }
    .logo-icon { width: 36px; height: 36px; background: var(--gradient-gold); border-radius: 10px; display: flex; align-items: center; justify-content: center; }
    .logo-icon svg { width: 20px; height: 20px; color: var(--bg-primary); }
    .logo-text { font-family: var(--font-display); font-size: 1.35rem; color: var(--text-primary); }
    .breadcrumb { display: flex; align-items: center; gap: 8px; font-size: 0.9rem; color: var(--text-muted); }
    .breadcrumb a { color: var(--text-secondary); text-decoration: none; }
    .breadcrumb a:hover { color: var(--accent); }
    .breadcrumb svg { width: 16px; height: 16px; }
    .content-wrapper { padding-top: 72px; display: flex; min-height: 100vh; }
    .sidebar { width: 280px; background: var(--bg-secondary); border-right: 1px solid var(--border); position: fixed; top: 72px; bottom: 0; overflow-y: auto; padding: 24px 0; }
    .sidebar-header { padding: 0 20px 16px; border-bottom: 1px solid var(--border); margin-bottom: 16px; }
    .sidebar-title { font-size: 0.75rem; text-transform: uppercase; letter-spacing: 0.1em; color: var(--text-muted); margin-bottom: 8px; }
    .domain-title { font-size: 1rem; font-weight: 600; color: var(--accent); }
    .chapter-list { list-style: none; }
    .chapter-item { border-bottom: 1px solid var(--border); }
    .chapter-link { display: flex; align-items: center; gap: 12px; padding: 14px 20px; color: var(--text-secondary); text-decoration: none; font-size: 0.9rem; transition: all 0.2s ease; }
    .chapter-link:hover { background: var(--bg-tertiary); color: var(--text-primary); }
    .chapter-link.active { background: var(--accent-dim); color: var(--accent); border-left: 3px solid var(--accent); }
    .chapter-number { width: 24px; height: 24px; border-radius: 50%; background: var(--bg-tertiary); display: flex; align-items: center; justify-content: center; font-size: 0.75rem; font-weight: 600; flex-shrink: 0; }
    .sidebar-section-label { padding: 12px 20px 6px; font-size: 0.7rem; text-transform: uppercase; letter-spacing: 0.08em; color: var(--accent); font-weight: 600; }
    .main-content { margin-left: 280px; flex: 1; padding: 48px 64px; max-width: 900px; }
    .chapter-header { margin-bottom: 48px; }
    .chapter-badge { display: inline-flex; align-items: center; gap: 8px; padding: 6px 12px; background: var(--bg-tertiary); border: 1px solid var(--border); border-radius: 20px; font-size: 0.8rem; color: var(--text-muted); margin-bottom: 16px; }
    h1 { font-family: var(--font-display); font-size: 2.5rem; margin-bottom: 16px; line-height: 1.2; }
    .chapter-meta { display: flex; gap: 24px; color: var(--text-muted); font-size: 0.9rem; }
    .coming-soon-container { display: flex; flex-direction: column; align-items: center; justify-content: center; padding: 80px 40px; text-align: center; }
    .coming-soon-icon { width: 80px; height: 80px; background: var(--accent-dim); border-radius: 50%; display: flex; align-items: center; justify-content: center; margin-bottom: 32px; }
    .coming-soon-icon svg { width: 40px; height: 40px; color: var(--accent); }
    .coming-soon-title { font-family: var(--font-display); font-size: 2rem; margin-bottom: 16px; color: var(--text-primary); }
    .coming-soon-text { color: var(--text-secondary); font-size: 1.1rem; max-width: 500px; margin-bottom: 32px; line-height: 1.8; }
    .coming-soon-note { background: var(--bg-card); border: 1px solid var(--border); border-radius: var(--radius-md); padding: 20px 24px; color: var(--text-muted); font-size: 0.9rem; }
    .nav-buttons { display: flex; justify-content: space-between; margin-top: 64px; padding-top: 32px; border-top: 1px solid var(--border); }
    .nav-btn { display: flex; align-items: center; gap: 12px; padding: 16px 24px; background: var(--bg-card); border: 1px solid var(--border); border-radius: var(--radius-md); text-decoration: none; color: var(--text-secondary); transition: all 0.2s ease; }
    .nav-btn:hover { border-color: var(--accent); color: var(--text-primary); }
    .nav-btn-label { font-size: 0.8rem; color: var(--text-muted); }
    .nav-btn-title { font-weight: 600; color: var(--text-primary); }
    .content-section { margin-bottom: 48px; }
    .content-section h2 { font-family: var(--font-display); font-size: 1.8rem; margin-bottom: 20px; padding-bottom: 12px; border-bottom: 1px solid var(--border); }
    .content-section h3 { font-size: 1.25rem; font-weight: 600; margin: 28px 0 12px; color: var(--text-primary); }
    .content-section h4 { font-size: 1.05rem; font-weight: 600; margin: 20px 0 8px; color: var(--text-secondary); }
    .content-section p { color: var(--text-secondary); margin-bottom: 16px; font-size: 0.95rem; }
    .content-section ul, .content-section ol { color: var(--text-secondary); margin: 0 0 16px 24px; font-size: 0.95rem; }
    .content-section li { margin-bottom: 6px; }
    .key-term { color: var(--accent); font-weight: 600; }
    .definition-box { background: var(--bg-card); border-left: 3px solid var(--accent); border-radius: 0 var(--radius-sm) var(--radius-sm) 0; padding: 16px 20px; margin: 16px 0; }
    .definition-box strong { color: var(--text-primary); }
    .definition-box p { margin-bottom: 0; }
    .example-box { background: rgba(245, 158, 11, 0.06); border-left: 3px solid #f59e0b; border-radius: 0 var(--radius-sm) var(--radius-sm) 0; padding: 16px 20px; margin: 16px 0; }
    .example-box strong { color: #f59e0b; }
    .example-box p { margin-bottom: 0; }
    .clinical-note { background: rgba(59, 130, 246, 0.08); border-left: 3px solid #3b82f6; border-radius: 0 var(--radius-sm) var(--radius-sm) 0; padding: 16px 20px; margin: 16px 0; }
    .clinical-note strong { color: #3b82f6; }
    .clinical-note p { margin-bottom: 0; }
    .citation { font-size: 0.85rem; color: var(--text-muted); font-style: italic; }
    table { width: 100%; border-collapse: collapse; margin: 16px 0; font-size: 0.9rem; }
    th { background: var(--bg-tertiary); color: var(--text-primary); padding: 10px 14px; text-align: left; border: 1px solid var(--border); font-weight: 600; }
    td { padding: 10px 14px; border: 1px solid var(--border); color: var(--text-secondary); }
    @media (max-width: 1024px) { .sidebar { display: none; } .main-content { margin-left: 0; padding: 32px 24px; } }
    .chapter-actions { display: flex; gap: 12px; margin-bottom: 32px; flex-wrap: wrap; }
    .action-btn { display: inline-flex; align-items: center; gap: 8px; padding: 10px 20px; border-radius: 8px; font-size: 0.85rem; font-weight: 500; text-decoration: none; transition: all 0.2s ease; }
    .flashcard-btn { background: var(--bg-tertiary); border: 1px solid var(--border-light); color: var(--text-secondary); }
    .flashcard-btn:hover { background: var(--bg-card); color: var(--text-primary); border-color: var(--accent); }
    .quiz-btn { background: var(--bg-tertiary); border: 1px solid var(--border-light); color: var(--text-secondary); }
    .quiz-btn:hover { background: var(--bg-card); color: var(--text-primary); border-color: var(--accent); }
    .mastery-btn { background: linear-gradient(135deg, #f59e0b 0%, #ef4444 100%); border: none; color: #fff; font-weight: 600; box-shadow: 0 2px 12px rgba(245, 158, 11, 0.3); }
    .mastery-btn:hover { box-shadow: 0 4px 20px rgba(245, 158, 11, 0.5); transform: translateY(-1px); }
    .upgrade-modal-overlay { display:none; position:fixed; top:0; left:0; right:0; bottom:0; background:rgba(0,0,0,0.7); z-index:1000; align-items:center; justify-content:center; }
    .upgrade-modal-overlay.visible { display:flex; }
    .upgrade-modal { background:var(--bg-card); border:1px solid var(--border); border-radius:var(--radius-lg,16px); padding:40px; max-width:420px; width:90%; text-align:center; }
    .upgrade-modal-icon { width:64px; height:64px; margin:0 auto 20px; background:linear-gradient(135deg,#f59e0b 0%,#ef4444 100%); border-radius:50%; display:flex; align-items:center; justify-content:center; }
    .upgrade-modal-icon svg { color:#fff; }
    .upgrade-modal h3 { font-size:1.25rem; margin-bottom:8px; color:var(--text-primary); }
    .upgrade-modal p { color:var(--text-secondary); margin-bottom:24px; font-size:0.9rem; line-height:1.6; }
    .upgrade-modal-actions { display:flex; gap:12px; }
    .upgrade-modal-actions a, .upgrade-modal-actions button { flex:1; padding:12px; border-radius:8px; font-size:0.85rem; font-weight:600; cursor:pointer; text-decoration:none; text-align:center; border:none; }
    .upgrade-modal .btn-dismiss { background:var(--bg-tertiary); color:var(--text-secondary); border:1px solid var(--border); }
    .upgrade-modal .btn-upgrade { background:linear-gradient(135deg,#f59e0b 0%,#ef4444 100%); color:#fff; }
  </style>
</head>
<body>
  <nav class="top-nav">
    <div class="nav-left">
      <a href="../../index.html" class="logo">
        <div class="logo-icon"><svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2.5"><path d="M12 2L2 7l10 5 10-5-10-5zM2 17l10 5 10-5M2 12l10 5 10-5"/></svg></div>
        <span class="logo-text">MasteryPage</span>
      </a>
      <div class="breadcrumb">
        <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M9 18l6-6-6-6"/></svg>
        <a href="../../textbook.html">Textbook</a>
        <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M9 18l6-6-6-6"/></svg>
        <a href="index.html">Domain 9</a>
        <svg viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M9 18l6-6-6-6"/></svg>
        <span>Antidepressants</span>
      </div>
    </div>
  </nav>
  <div class="content-wrapper">
    <aside class="sidebar">
      <div class="sidebar-header">
        <div class="sidebar-title">Domain 9</div>
        <div class="domain-title">Psychopharmacology &amp; Ethics</div>
      </div>
      <ul class="chapter-list">
        <li class="chapter-item"><a href="index.html" class="chapter-link"><span class="chapter-number">0</span>Overview</a></li>
        <li class="sidebar-section-label">Part A: APA Ethics Code</li>
        <li class="chapter-item"><a href="ethics-overview.html" class="chapter-link"><span class="chapter-number">A0</span>Overview & Principles</a></li>
        <li class="chapter-item"><a href="resolving-ethical-issues.html" class="chapter-link"><span class="chapter-number">A1</span>Resolving Ethical Issues</a></li>
        <li class="chapter-item"><a href="competence.html" class="chapter-link"><span class="chapter-number">A2</span>Competence</a></li>
        <li class="chapter-item"><a href="human-relations.html" class="chapter-link"><span class="chapter-number">A3</span>Human Relations</a></li>
        <li class="chapter-item"><a href="privacy-confidentiality.html" class="chapter-link"><span class="chapter-number">A4</span>Privacy & Confidentiality</a></li>
        <li class="chapter-item"><a href="advertising.html" class="chapter-link"><span class="chapter-number">A5</span>Advertising</a></li>
        <li class="chapter-item"><a href="record-keeping-fees.html" class="chapter-link"><span class="chapter-number">A6</span>Record Keeping & Fees</a></li>
        <li class="chapter-item"><a href="education-training.html" class="chapter-link"><span class="chapter-number">A7</span>Education & Training</a></li>
        <li class="chapter-item"><a href="research-publication.html" class="chapter-link"><span class="chapter-number">A8</span>Research & Publication</a></li>
        <li class="chapter-item"><a href="assessment-ethics.html" class="chapter-link"><span class="chapter-number">A9</span>Assessment</a></li>
        <li class="chapter-item"><a href="therapy-ethics.html" class="chapter-link"><span class="chapter-number">A10</span>Therapy</a></li>
        <li class="sidebar-section-label">Part B: Psychopharmacology</li>
        <li class="chapter-item"><a href="pharma-foundations.html" class="chapter-link"><span class="chapter-number">B0</span>Pharmacological Foundations</a></li>
        <li class="chapter-item"><a href="antidepressants.html" class="chapter-link active"><span class="chapter-number">B1</span>Antidepressants</a></li>
        <li class="chapter-item"><a href="antipsychotics.html" class="chapter-link"><span class="chapter-number">B2</span>Antipsychotics</a></li>
        <li class="chapter-item"><a href="anxiolytics-sedatives.html" class="chapter-link"><span class="chapter-number">B3</span>Anxiolytics & Sedatives</a></li>
        <li class="chapter-item"><a href="mood-stabilizers.html" class="chapter-link"><span class="chapter-number">B4</span>Mood Stabilizers</a></li>
        <li class="chapter-item"><a href="stimulants-adhd.html" class="chapter-link"><span class="chapter-number">B5</span>Stimulants & ADHD Meds</a></li>
        <li class="sidebar-section-label">Appendix</li>
        <li class="chapter-item"><a href="professional-issues.html" class="chapter-link"><span class="chapter-number">+</span>Professional Issues</a></li>
      </ul>
    </aside>
    <main class="main-content">
      <header class="chapter-header">
        <div class="chapter-badge">Chapter B1 of 17</div>
        <h1>Antidepressants</h1>
        <div class="chapter-meta">
          <span>SSRIs, SNRIs, TCAs, MAOIs, serotonin syndrome</span>
        </div>
      </header>
      <div class="chapter-actions">
        <a href="javascript:void(0)" onclick="chapterAction('flashcards')" class="action-btn flashcard-btn">
          <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><rect x="2" y="3" width="20" height="14" rx="2"/><line x1="8" y1="21" x2="16" y2="21"/><line x1="12" y1="17" x2="12" y2="21"/></svg>
          Flashcards
        </a>
        <a href="javascript:void(0)" onclick="chapterAction('quiz-fundamental', 9)" class="action-btn quiz-btn">
          <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><path d="M9 11l3 3L22 4"/><path d="M21 12v7a2 2 0 01-2 2H5a2 2 0 01-2-2V5a2 2 0 012-2h11"/></svg>
          Quick Quiz: Fundamental
        </a>
        <a href="javascript:void(0)" onclick="chapterAction('advanced-learning', 9)" class="action-btn mastery-btn">
          <svg width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polygon points="12 2 15.09 8.26 22 9.27 17 14.14 18.18 21.02 12 17.77 5.82 21.02 7 14.14 2 9.27 8.91 8.26 12 2"/></svg>
          Advanced Learning
        </a>
      </div>
<section class="content-section">
        <h2>Introduction to Antidepressant Medications</h2>
        <p>Antidepressants are among the most commonly prescribed psychotropic medications. They are used to treat major depressive disorder, anxiety disorders, OCD, PTSD, chronic pain, and other conditions. Understanding the major classes of antidepressants -- their mechanisms, side effects, and clinical considerations -- is essential for the EPPP.</p>
        <p>Antidepressants generally take <strong>2-6 weeks</strong> to reach full therapeutic effect, although side effects may begin immediately. This delay is thought to relate to downstream neuroplastic changes rather than the acute increase in neurotransmitter availability.</p>
      </section>

      <section class="content-section">
        <h2>Selective Serotonin Reuptake Inhibitors (SSRIs)</h2>
        <p><span class="key-term">SSRIs</span> are the most commonly prescribed class of antidepressants and are generally considered first-line treatment for depression and many anxiety disorders due to their relatively favorable side effect profile.</p>

        <h3>Mechanism of Action</h3>
        <p>SSRIs selectively block the reuptake of <span class="key-term">serotonin (5-HT)</span> at the presynaptic neuron, increasing the availability of serotonin in the synaptic cleft. They have minimal effects on norepinephrine and dopamine reuptake.</p>

        <h3>Common SSRIs</h3>
        <table>
          <tr><th>Generic Name</th><th>Brand Name</th><th>Notable Features</th></tr>
          <tr><td>Fluoxetine</td><td>Prozac</td><td>Longest half-life (~2-6 days; active metabolite norfluoxetine ~4-16 days); approved for children/adolescents with depression; less risk of discontinuation syndrome</td></tr>
          <tr><td>Sertraline</td><td>Zoloft</td><td>Mild dopamine reuptake inhibition; commonly prescribed for PTSD; considered safe in cardiac patients</td></tr>
          <tr><td>Paroxetine</td><td>Paxil</td><td>Most anticholinergic of the SSRIs; short half-life leading to higher discontinuation risk; associated with weight gain; NOT recommended in pregnancy (Category D)</td></tr>
          <tr><td>Citalopram</td><td>Celexa</td><td>Most selective SSRI; dose-dependent QT prolongation risk; FDA max dose 40 mg/day</td></tr>
          <tr><td>Escitalopram</td><td>Lexapro</td><td>S-enantiomer of citalopram; may have fewer drug interactions; commonly used for generalized anxiety disorder</td></tr>
          <tr><td>Fluvoxamine</td><td>Luvox</td><td>Primarily used for OCD; significant drug-drug interactions via CYP enzymes</td></tr>
        </table>

        <h3>Common Side Effects of SSRIs</h3>
        <ul>
          <li><strong>Sexual dysfunction</strong> (decreased libido, anorgasmia, erectile dysfunction) -- most common reason for discontinuation</li>
          <li>Gastrointestinal disturbances (nausea, diarrhea)</li>
          <li>Headache, insomnia, or drowsiness</li>
          <li>Weight gain (especially paroxetine) or weight loss</li>
          <li>Increased anxiety initially (may worsen before improving)</li>
          <li><strong>Discontinuation syndrome</strong> with abrupt cessation (dizziness, nausea, "brain zaps," irritability)</li>
        </ul>
      </section>

      <section class="content-section">
        <h2>Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)</h2>
        <p><span class="key-term">SNRIs</span> block the reuptake of both serotonin and norepinephrine, providing a dual mechanism that may be beneficial for patients who do not respond to SSRIs alone. They are also used for chronic pain conditions, fibromyalgia, and neuropathic pain.</p>

        <h3>Common SNRIs</h3>
        <table>
          <tr><th>Generic Name</th><th>Brand Name</th><th>Notable Features</th></tr>
          <tr><td>Venlafaxine</td><td>Effexor</td><td>At low doses, primarily serotonergic; norepinephrine effects emerge at higher doses; may increase blood pressure; significant discontinuation syndrome</td></tr>
          <tr><td>Duloxetine</td><td>Cymbalta</td><td>FDA-approved for MDD, GAD, fibromyalgia, diabetic neuropathic pain, and chronic musculoskeletal pain; hepatotoxicity risk (avoid in liver disease)</td></tr>
          <tr><td>Desvenlafaxine</td><td>Pristiq</td><td>Active metabolite of venlafaxine; fewer drug interactions; simpler dosing</td></tr>
          <tr><td>Levomilnacipran</td><td>Fetzima</td><td>Greater selectivity for norepinephrine than serotonin; may be more activating</td></tr>
        </table>

        <h3>Side Effects of SNRIs</h3>
        <ul>
          <li>Similar to SSRIs (sexual dysfunction, nausea, headache)</li>
          <li><strong>Elevated blood pressure</strong> (especially venlafaxine at higher doses) -- blood pressure monitoring recommended</li>
          <li>Increased sweating</li>
          <li>Discontinuation syndrome (particularly severe with venlafaxine due to its short half-life)</li>
        </ul>
      </section>

      <section class="content-section">
        <h2>Tricyclic Antidepressants (TCAs)</h2>
        <p><span class="key-term">TCAs</span> were the first widely used antidepressants but have largely been replaced by SSRIs and SNRIs as first-line treatments due to their significant side effect profile and lethality in overdose. They remain useful for treatment-resistant depression and certain other conditions.</p>

        <h3>Mechanism of Action</h3>
        <p>TCAs block the reuptake of both serotonin and norepinephrine but also block histamine (H1), acetylcholine (muscarinic), and alpha-1 adrenergic receptors, which produces many of their side effects.</p>

        <h3>Common TCAs</h3>
        <table>
          <tr><th>Generic Name</th><th>Brand Name</th><th>Notable Features</th></tr>
          <tr><td>Amitriptyline</td><td>Elavil</td><td>Highly sedating; used for chronic pain and migraine prophylaxis; most anticholinergic TCA</td></tr>
          <tr><td>Imipramine</td><td>Tofranil</td><td>First TCA discovered; used for enuresis in children; panic disorder</td></tr>
          <tr><td>Nortriptyline</td><td>Pamelor</td><td>Active metabolite of amitriptyline; less sedating; therapeutic window for blood levels</td></tr>
          <tr><td>Clomipramine</td><td>Anafranil</td><td>Most serotonergic TCA; first-line pharmacotherapy for OCD</td></tr>
          <tr><td>Desipramine</td><td>Norpramin</td><td>Most noradrenergic TCA; least sedating; less anticholinergic</td></tr>
        </table>

        <h3>Side Effects of TCAs</h3>
        <ul>
          <li><strong>Anticholinergic effects</strong> (dry mouth, constipation, urinary retention, blurred vision, tachycardia) -- remember "can't see, can't pee, can't spit, can't sh*t"</li>
          <li><strong>Sedation</strong> (due to histamine blockade)</li>
          <li><strong>Orthostatic hypotension</strong> (due to alpha-1 blockade)</li>
          <li><strong>Weight gain</strong></li>
          <li><strong>Cardiac toxicity</strong> -- fatal in overdose due to cardiac arrhythmias (QT prolongation, heart block). This is why TCAs are dangerous in suicidal patients.</li>
          <li>Lowered seizure threshold</li>
        </ul>
        <div class="clinical-note">
          <strong>EPPP Tip</strong>
          <p>TCAs are <strong>lethal in overdose</strong> due to cardiac arrhythmias. This is a critical clinical consideration and a frequently tested EPPP fact. For this reason, TCAs are prescribed cautiously (if at all) to patients with suicidal ideation. A one-week supply of TCAs can be lethal in overdose.</p>
        </div>
      </section>

      <section class="content-section">
        <h2>Monoamine Oxidase Inhibitors (MAOIs)</h2>
        <p><span class="key-term">MAOIs</span> are the oldest class of antidepressants. They are now typically reserved for treatment-resistant depression and atypical depression because of their potentially dangerous drug and food interactions.</p>

        <h3>Mechanism of Action</h3>
        <p>MAOIs inhibit the enzyme <span class="key-term">monoamine oxidase</span>, which normally breaks down serotonin, norepinephrine, and dopamine. By inhibiting this enzyme, MAOIs increase the availability of all three monoamines.</p>
        <ul>
          <li><strong>MAO-A</strong> preferentially metabolizes serotonin and norepinephrine</li>
          <li><strong>MAO-B</strong> preferentially metabolizes dopamine (selegiline, used in Parkinson's disease, is selective for MAO-B at low doses)</li>
        </ul>

        <h3>Common MAOIs</h3>
        <ul>
          <li><strong>Phenelzine (Nardil)</strong> -- irreversible, nonselective</li>
          <li><strong>Tranylcypromine (Parnate)</strong> -- irreversible, nonselective</li>
          <li><strong>Selegiline (Emsam)</strong> -- available as a transdermal patch; at low doses, selective for MAO-B; dietary restrictions may not be required at lowest patch dose</li>
        </ul>

        <h3>The Tyramine Crisis (Hypertensive Crisis)</h3>
        <div class="definition-box">
          <strong>Tyramine Crisis</strong>
          <p>Patients taking MAOIs must follow strict dietary restrictions to avoid <span class="key-term">tyramine</span>-containing foods. Tyramine is normally broken down by MAO in the gut. When MAO is inhibited, tyramine accumulates and causes the release of large amounts of norepinephrine, leading to a potentially fatal <strong>hypertensive crisis</strong> (severe headache, rapid heart rate, stiff neck, nausea, stroke, death).</p>
        </div>
        <p>Foods to avoid while taking MAOIs include:</p>
        <ul>
          <li>Aged cheeses (cheddar, Swiss, parmesan, blue cheese)</li>
          <li>Cured or smoked meats (salami, pepperoni, smoked fish)</li>
          <li>Fermented foods (sauerkraut, kimchi, soy sauce)</li>
          <li>Draft beer, red wine</li>
          <li>Broad (fava) beans</li>
          <li>Certain dietary supplements and over-the-counter cold medications containing pseudoephedrine or phenylephrine</li>
        </ul>

        <h3>Drug Interactions with MAOIs</h3>
        <p>MAOIs have dangerous interactions with many medications, including SSRIs, SNRIs, TCAs, meperidine (Demerol), dextromethorphan, and sympathomimetic drugs. A <strong>washout period of at least 2 weeks</strong> is required when switching between MAOIs and serotonergic medications (5 weeks for fluoxetine due to its long half-life).</p>
      </section>

      <section class="content-section">
        <h2>Atypical Antidepressants</h2>
        <p>Several antidepressants do not fit neatly into the above categories and are classified as <span class="key-term">atypical antidepressants</span>.</p>

        <h3>Bupropion (Wellbutrin)</h3>
        <ul>
          <li><strong>Mechanism:</strong> Norepinephrine-dopamine reuptake inhibitor (NDRI); does NOT affect serotonin</li>
          <li><strong>Uses:</strong> Depression, smoking cessation (marketed as Zyban), ADHD (off-label)</li>
          <li><strong>Advantages:</strong> No sexual dysfunction (may actually improve libido); no weight gain (may cause weight loss); activating rather than sedating</li>
          <li><strong>Risks:</strong> Lowers seizure threshold (contraindicated in patients with seizure disorders, eating disorders, or those undergoing abrupt alcohol withdrawal); may increase anxiety</li>
        </ul>

        <h3>Mirtazapine (Remeron)</h3>
        <ul>
          <li><strong>Mechanism:</strong> Noradrenergic and specific serotonergic antidepressant (NaSSA); blocks alpha-2 autoreceptors (increasing NE and 5-HT release) and 5-HT2 and 5-HT3 receptors; potent H1 antagonist</li>
          <li><strong>Uses:</strong> Depression, especially with insomnia, poor appetite, or weight loss</li>
          <li><strong>Side effects:</strong> Significant sedation and weight gain (due to H1 blockade); increased appetite; useful when these "side effects" are actually therapeutic goals</li>
          <li><strong>Advantages:</strong> Minimal sexual dysfunction; helpful for nausea (5-HT3 blockade)</li>
        </ul>

        <h3>Trazodone (Desyrel)</h3>
        <ul>
          <li><strong>Mechanism:</strong> Serotonin antagonist and reuptake inhibitor (SARI)</li>
          <li><strong>Uses:</strong> Primarily used as a sleep aid at low doses; antidepressant at higher doses (rarely used this way due to sedation)</li>
          <li><strong>Side effects:</strong> Sedation, orthostatic hypotension, <span class="key-term">priapism</span> (rare but serious -- prolonged painful erection requiring emergency treatment)</li>
        </ul>
      </section>

      <section class="content-section">
        <h2>Serotonin Syndrome</h2>
        <div class="definition-box">
          <strong>Serotonin Syndrome</strong>
          <p><span class="key-term">Serotonin syndrome</span> is a potentially life-threatening condition caused by excessive serotonergic activity, typically resulting from combining two or more serotonergic medications (e.g., SSRI + MAOI, SSRI + tramadol, SSRI + St. John's Wort). It requires immediate medical attention.</p>
        </div>
        <h3>Clinical Triad of Serotonin Syndrome</h3>
        <ol>
          <li><strong>Cognitive/behavioral changes:</strong> Agitation, confusion, hypomania, restlessness</li>
          <li><strong>Autonomic instability:</strong> Hyperthermia, tachycardia, diaphoresis (sweating), diarrhea, fluctuating blood pressure</li>
          <li><strong>Neuromuscular abnormalities:</strong> Tremor, myoclonus (muscle jerking), hyperreflexia, rigidity, clonus</li>
        </ol>
        <p><strong>Treatment:</strong> Discontinue all serotonergic agents; supportive care; cyproheptadine (a serotonin antagonist) may be used in severe cases; benzodiazepines for agitation.</p>
      </section>

      <section class="content-section">
        <h2>The FDA Black Box Warning</h2>
        <p>In 2004, the FDA issued a <span class="key-term">black box warning</span> -- the strongest warning the FDA can require -- for all antidepressants regarding the increased risk of <strong>suicidal thinking and behavior in children, adolescents, and young adults (up to age 24)</strong> during the initial weeks of treatment.</p>
        <ul>
          <li>The warning applies to all antidepressants, not just SSRIs</li>
          <li>The risk appears to be highest during the first 1-2 months of treatment or after dose changes</li>
          <li>The mechanism is thought to involve an initial increase in energy and motivation before mood fully improves, potentially enabling a suicidal individual to act on preexisting ideation</li>
          <li>Close monitoring is recommended during the initial period of treatment, especially in young patients</li>
          <li>The warning does NOT state that antidepressants should not be prescribed to young people; the benefits generally outweigh the risks, but careful monitoring is essential</li>
        </ul>
        <div class="clinical-note">
          <strong>EPPP Tip</strong>
          <p>The black box warning is limited to <strong>ages 24 and under</strong>. For adults aged 25-64, antidepressants showed no increased suicidality, and for adults 65+, antidepressants appeared to <em>reduce</em> suicidal risk. The only SSRI FDA-approved for use in children with depression is <strong>fluoxetine</strong> (ages 8+).</p>
        </div>
      </section>

      <section class="content-section">
        <h2>Key Takeaways for the EPPP</h2>
        <ul>
          <li><strong>SSRIs</strong> are first-line treatment for depression and anxiety; primary side effects include sexual dysfunction and GI disturbance.</li>
          <li><strong>Fluoxetine</strong> has the longest half-life and is the only SSRI FDA-approved for pediatric depression.</li>
          <li><strong>SNRIs</strong> block both serotonin and norepinephrine reuptake; venlafaxine can raise blood pressure.</li>
          <li><strong>TCAs</strong> are lethal in overdose due to cardiac arrhythmias; cause anticholinergic side effects and sedation.</li>
          <li><strong>Clomipramine</strong> is the most serotonergic TCA and the first-line pharmacotherapy for OCD.</li>
          <li><strong>MAOIs</strong> require strict dietary restrictions to avoid tyramine-induced hypertensive crisis; require a 2-week washout before switching to serotonergic drugs.</li>
          <li><strong>Bupropion</strong> (NDRI) does not cause sexual dysfunction, aids in smoking cessation, but lowers seizure threshold.</li>
          <li><strong>Mirtazapine</strong> causes sedation and weight gain but no sexual dysfunction; useful when appetite stimulation and sleep are needed.</li>
          <li><strong>Serotonin syndrome</strong> results from combining serotonergic agents and presents with the triad of cognitive changes, autonomic instability, and neuromuscular hyperactivity.</li>
          <li>The <strong>FDA black box warning</strong> applies to suicidality risk in patients aged 24 and under during initial antidepressant treatment.</li>
        </ul>
      </section>
      <div class="nav-buttons">
        <a href="pharma-foundations.html" class="nav-btn">
          <svg viewBox="0 0 24 24" width="20" height="20" fill="none" stroke="currentColor" stroke-width="2"><path d="M15 18l-6-6 6-6"/></svg>
          <div>
            <div class="nav-btn-label">Previous</div>
            <div class="nav-btn-title">Pharmacological Foundations</div>
          </div>
        </a>
        <a href="antipsychotics.html" class="nav-btn">
          <div style="text-align: right;">
            <div class="nav-btn-label">Next</div>
            <div class="nav-btn-title">Antipsychotics</div>
          </div>
          <svg viewBox="0 0 24 24" width="20" height="20" fill="none" stroke="currentColor" stroke-width="2"><path d="M9 18l6-6-6-6"/></svg>
        </a>
      </div>
    </main>
  </div>
  <div class="upgrade-modal-overlay" id="upgradeModal" onclick="if(event.target===this)this.classList.remove('visible')">
    <div class="upgrade-modal">
      <div class="upgrade-modal-icon"><svg width="28" height="28" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2"><polygon points="12 2 15.09 8.26 22 9.27 17 14.14 18.18 21.02 12 17.77 5.82 21.02 7 14.14 2 9.27 8.91 8.26 12 2"/></svg></div>
      <h3>Upgrade to Unlock</h3>
      <p>Flashcards, Quick Quizzes, and Mastery Quizzes are available on paid plans. Upgrade today to test your knowledge and track your progress.</p>
      <div class="upgrade-modal-actions">
        <button class="btn-dismiss" onclick="document.getElementById('upgradeModal').classList.remove('visible')">Maybe Later</button>
        <a href="../../index.html" class="btn-upgrade">View Plans</a>
      </div>
    </div>
  </div>
  <script>
    function chapterAction(action, domainNum) {
      var tier = 'free';
      try {
        var s = sessionStorage.getItem('passeppp_session');
        if (s) { tier = JSON.parse(s).tier || 'free'; }
      } catch(e) {}
      if (tier === 'free') {
        document.getElementById('upgradeModal').classList.add('visible');
        return;
      }
      if (action === 'flashcards') window.location.href = '../../index.html';
      else if (action === 'quiz-fundamental') window.location.href = '../../index.html';
      else if (action === 'advanced-learning') { var ch = document.querySelector('h1').textContent.trim(); window.location.href = '../../index.html'; }
    }
  </script>
</body>
</html>
